Clinical Trial Update: Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

Phase 2 trial updates the evaluation of low-dose recombinant human IL-2 for rheumatoid arthritis, with results posted after completion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• recombinant human IL-2 (low-dose) (interleukin-2)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Rheumatoid Arthritis | Phase 2 | Status: COMPLETED | Results posted: 2019-09-09